Vaccine seen to work on hepatitis
By Tan Ee Lyn |
August 24, 2010, Tuesday
|
Print Edition
Print Edition
AN experimental vaccine appears to be safe and effective in protecting people against hepatitis E infection, a trial in China has found.
Hepatitis E virus is shed in feces and spread via tainted water and food.
Even though most people recover, it can cause severe illness in elderly people and has a mortality rate of 1 to 3 percent.
The virus can kill between 5 to 25 percent of pregnant women and those who survive can suffer high rates of miscarriage.
In a phase 3 trial involving 97,356 healthy participants in east China's Jiangsu Province, half were given the China-made vaccine and the other half placebo.
The vaccine made by Xiamen Innovax Biotech was given in three doses. The second was given after a month; the third was given after six months.
Within a year after the third dose, 15 of the participants who were given placebo were found infected with hepatitis E, the researchers said in a paper published in The Lancet yesterday.
No one in the vaccine group was infected.
"In our trial, we found the vaccine well tolerated and efficacious for a general adult population.
"Further studies are needed to assess the safety and to support the benefits of the vaccine for pregnant women and for people younger than 15 years or older than 65 years," the researchers wrote in a statement.
"During a hepatitis E outbreak, or for travelers to an endemic area, protection can be quickly obtained by two vaccine doses given within one month."
No serious side effects were found to be linked to the vaccine, they said.
The researchers were led by Xia Ningshao at the Institute of Diagnostics and Vaccine Development in Infectious Diseases in Xiamen University in the southern Fujian Province.
Hepatitis E infection puts people with chronic liver illnesses at added risk.
The authors recommended that such people be vaccinated against hepatitis E.
However, they said that because the study excluded people with chronic liver disease, more research would be needed to assess the benefits of such a vaccine for these people.
Hepatitis E virus is shed in feces and spread via tainted water and food.
Even though most people recover, it can cause severe illness in elderly people and has a mortality rate of 1 to 3 percent.
The virus can kill between 5 to 25 percent of pregnant women and those who survive can suffer high rates of miscarriage.
In a phase 3 trial involving 97,356 healthy participants in east China's Jiangsu Province, half were given the China-made vaccine and the other half placebo.
The vaccine made by Xiamen Innovax Biotech was given in three doses. The second was given after a month; the third was given after six months.
Within a year after the third dose, 15 of the participants who were given placebo were found infected with hepatitis E, the researchers said in a paper published in The Lancet yesterday.
No one in the vaccine group was infected.
"In our trial, we found the vaccine well tolerated and efficacious for a general adult population.
"Further studies are needed to assess the safety and to support the benefits of the vaccine for pregnant women and for people younger than 15 years or older than 65 years," the researchers wrote in a statement.
"During a hepatitis E outbreak, or for travelers to an endemic area, protection can be quickly obtained by two vaccine doses given within one month."
No serious side effects were found to be linked to the vaccine, they said.
The researchers were led by Xia Ningshao at the Institute of Diagnostics and Vaccine Development in Infectious Diseases in Xiamen University in the southern Fujian Province.
Hepatitis E infection puts people with chronic liver illnesses at added risk.
The authors recommended that such people be vaccinated against hepatitis E.
However, they said that because the study excluded people with chronic liver disease, more research would be needed to assess the benefits of such a vaccine for these people.
- About Us
- |
- Terms of Use
- |
-
RSS - |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 娌狪CP璇侊細娌狪CP澶05050403鍙-1
- |
- 浜掕仈缃戞柊闂讳俊鎭湇鍔¤鍙瘉锛31120180004
- |
- 缃戠粶瑙嗗惉璁稿彲璇侊細0909346
- |
- 骞挎挱鐢佃鑺傜洰鍒朵綔璁稿彲璇侊細娌瓧绗354鍙
- |
- 澧炲肩數淇′笟鍔＄粡钀ヨ鍙瘉锛氭勃B2-20120012
Copyright 漏 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.
